NCT06870019|Recruiting
Hepatitis C Tracker Study
Effects of GPS Tracking on Patient Adherence to Hepatitis C Treatment Among People Experiencing Unsheltered Homelessness
Loading search results
Effects of GPS Tracking on Patient Adherence to Hepatitis C Treatment Among People Experiencing Unsheltered Homelessness
Sponsor study identifier
interventional
124
1 country
2
Study Start
August 8, 2025
Actual (reported)Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this study is to determine if GPS tracking can enhance adherence to hepatitis C treatment among patients diagnosed with hepatitis C infection who are also experiencing unsheltered homelessness and receiving street medicine. Research will compare medication adherence among participants randomly assigned to receive standard medical care for Hepatitis C versus the standard medical care for Hepatitis C along with GPS tracking assistance.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 7, 2025
Actual (reported)March 11, 2025
Actual (reported)August 8, 2025
Actual (reported)December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Medication Adherence Rate
Number of prescribed HCV pills taken (missing from pill organizer) versus number of HCV pills prescribed (present in pill organizer) per week, for each week of the 12-week treatment regimen
8-12 weeks
Length of treatment course
Number of weeks patient engaged in HCV medication treatment
8-12 weeks
Sustained virologic response
through study completion, an average of 24 weeks
Participants randomized to this study arm will receive the standard medical care for Hepatitis C.
Participants randomized to this study arm will receive the standard medical care for Hepatitis C and a GPS tracker device.
GPS tracker device
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
USC Street Medicine
Alhambra, California, 91803, United States
Ventura County Medical Center
Ventura, California, 93003, United States
Camilo Zaks, MD
University of Southern California, Keck School of Medicine of USC, Department of Family Medicine, USC Street Medicine
Tipu Kahn, MD
Ventura County Medical Center
First Submitted
February 7, 2025
First Posted
March 11, 2025
Study Start
August 8, 2025
Actual (reported)Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 29, 2025
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: